Referring to imidazopiridazinas Derivatives of formula (i), where a is a Group (a), (b), (c) or (d) Z is C (= o) n (H) - C (= o) n (H) R2, among others R2 is H, alkyl C1 - C6 C1 - C6 alkyl, Halo, among others R3 is aryl or heteroaryl - X - X X is o, S (NR6, p = o), among others, p is an integer from 0 to 2 n is an Enter Or 0 to 5 M is an integer of 0 to 6 and R4A R4D are H and H are r4c r4b, Halo, CN, oAmong others, R5 C1 - C6 is H, alkyl, N - (CH2) alquenilo C2 - C6, among others R7 R6 is H, alkyl, cycloalkyl - C1 - C6 C3, C6, among others.Preferred compounds are: N - cyclopropyl - (6 - [4 - (2-methoxyphenyl) sulfanyl)] - [8 - () - trifluoropropil) amino] imidazo [1,2-b] pyridazin-3 - il} - 2 - 3 - 4 - cyclopropyl methylbenzamide, n {- 8 - [(2 - hydroxy - 2-methylpropyl) amino] - 6 - [(4-hydroxyphenyl) sulfanyl] imidazo [1,2-b] pyridazin-3} - 2 - 3 - il methylbenzamide, among others. It also relates to a Pharmaceutical Composition and a preparation method.These compounds inhibit the kinase 1 (monopolar Spindle MPS - 1) and are useful in the treatment of diseases associated with uncontrolled Cell Proliferation, cellular immune response inadequate, inappropriate Cellular inflammatory response, among otherREFERIDA A DERIVADOS IMIDAZOPIRIDAZINAS DE FORMULA (I), DONDE A ES UN GRUPO (a), (b), (c) O (d) Z ES C(=O)N(H)R2, C(=S)N(H)R2, ENTRE OTROS R2 ES H, ALQUILO C1-C6, HALO-ALQUILO C1-C6, ENTRE OTROS R3 ES ARIL-X O HETEROARIL-X X ES O, NR6, S(=O)p, ENTRE OTROS p ES UN ENTERO DE 0 A 2 n ES UN ENTERO DE 0 A 5 m ES UN ENTERO DE 0 A 6 R4a Y R4d SON H R4b Y R4c SON H, HALO, CN, OH, ENTRE OTROS R5 ES H, ALQUILO C1-C6, (CH2)n-ALQUENILO C2-C6, ENTRE OTROS R6, R6 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-CICLOPROPIL-4-{6-[(2-METOXIFENIL)SULFANIL)]-8-[(3,3,3-TRIFLUOROPROPIL)AMINO]IMIDAZO[1,2-b]PIRIDAZIN-3-IL}-2-METILBENZAMIDA, N-CICLOPROPIL-4-{8-[(2-HIDROXI-2-METILPROPIL)AMINO]-6-[(4-HIDROXIFENIL)SULFANIL]-IMIDAZO[1,2-b]PIRIDAZIN-3-IL}-2-MET
